TPP1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: TPP1

NCBI ID: G1200

TPP1

TPP1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and fibromyalgia, are characterized by the persistent and severe inflammation of the central nervous system (CNS). These conditions can cause significant morbidity and economic burden, particularly in societies where the population is aging. The exact causes of these diseases are not well understood, but they are believed to involve an imbalance between pro-inflammatory and anti-inflammatory processes. Tissue-proximal protein 1 (TPP1), a cytoplasmic protein that belongs to the superfamily of the heat shock protein (HSP) family, has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases.

The HSP family of proteins plays a crucial role in the regulation of protein homeostasis, ensuring that cells maintain a proper balance of protein synthesis and degradation. TPP1, specifically, has been shown to be involved in the regulation of protein synthesis and stability, and its dysfunction has been implicated in the development and progression of several neurodegenerative diseases.

Disease-relevant functions of TPP1

The neurodegenerative diseases, including MS, ALS, and fibromyalgia, are characterized by the persistent and severe inflammation of the CNS. The exact causes of these diseases are not well understood, but they are believed to involve an imbalance between pro-inflammatory and anti-inflammatory processes. The inflammation in these diseases is thought to contribute to the neurotoxicity and progression of the disease.

TPP1 has been shown to be involved in the regulation of the expression of pro-inflammatory genes. Specifically, TPP1 has been shown to inhibit the activation and recruitment of immune cells to the site of inflammation, thereby reducing the production of pro-inflammatory cytokines. Additionally, TPP1 has been shown to enhance the production of anti-inflammatory cytokines, such as IL-10, by natural killer cells, thereby promoting an immune-mediated defense against inflammation.

TPP1 dysfunction in neurodegenerative diseases

TPP1 dysfunction has been observed in several neurodegenerative diseases, including MS, ALS, and fibromyalgia. Studies have shown that TPP1 levels are decreased in the brains of individuals with these diseases, and that TPP1 dysfunction is associated with the development and progression of these conditions.

In MS, TPP1 dysfunction has been observed in the central nervous system (CNS) and has been implicated in the development and progression of the disease. Several studies have shown that TPP1 levels are decreased in the brains of individuals with MS, and that TPP1 dysfunction is associated with the progression of the disease.

In ALS, TPP1 dysfunction has been observed in the brain and has been implicated in the development and progression of the disease. Studies have shown that TPP1 levels are decreased in the brains of individuals with ALS, and that TPP1 dysfunction is associated with the progression of the disease.

In fibromyalgia, TPP1 dysfunction has been observed in the peripheral tissues and has been implicated in the development and progression of the disease. Studies have shown that TPP1 levels are decreased in the blood of individuals with fibromyalgia, and that TPP1 dysfunction is associated with the progression of the disease.

Potential therapeutic applications of TPP1

The potential therapeutic applications of TPP1 are vast, as its dysfunction in neurodegenerative diseases has been implicated in the development and progression of these conditions. The following are some of the potential therapeutic applications of TPP1:

1.

Protein Name: Tripeptidyl Peptidase 1

Functions: Lysosomal serine protease with tripeptidyl-peptidase I activity (PubMed:11054422, PubMed:19038966, PubMed:19038967). May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases (PubMed:11054422, PubMed:19038966, PubMed:19038967). Requires substrates with an unsubstituted N-terminus (PubMed:19038966)

The "TPP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets